Iovance Biotherapeutics (IOVA) Set to Announce Earnings on Thursday

Iovance Biotherapeutics (NASDAQ:IOVA – Get Rating) is scheduled to be releasing its earnings data after the market closes on Thursday, May 5th. Analysts expect Iovance Biotherapeutics to post earnings of ($0.64) per share for the quarter. Persons that are interested in participating in the company’s earnings conference call can do so using this link.

Iovance Biotherapeutics (NASDAQ:IOVA – Get Rating) last posted its quarterly earnings data on Thursday, February 24th. The biotechnology company reported ($0.63) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.56) by ($0.07). During the same quarter in the prior year, the firm posted ($0.47) earnings per share. On average, analysts expect Iovance Biotherapeutics to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Shares of IOVA stock opened at $15.07 on Thursday. Iovance Biotherapeutics has a twelve month low of $12.18 and a twelve month high of $32.88. The stock has a market capitalization of $2.37 billion, a price-to-earnings ratio of -6.79 and a beta of 0.83. The stock has a fifty day simple moving average of $15.74 and a two-hundred day simple moving average of $18.03.

Several equities research analysts have weighed in on the company. Wells Fargo & Company lowered their target price on Iovance Biotherapeutics from $35.00 to $25.00 in a report on Wednesday, January 5th. Truist Financial lowered their target price on Iovance Biotherapeutics from $32.00 to $29.00 in a report on Thursday, April 7th. Stifel Nicolaus upgraded Iovance Biotherapeutics from a “hold” rating to a “buy” rating and upped their target price for the stock from $23.00 to $25.00 in a report on Friday, January 28th. Robert W. Baird upped their target price on Iovance Biotherapeutics from $30.00 to $34.00 and gave the stock an “outperform” rating in a report on Thursday, April 7th. Finally, StockNews.com began coverage on Iovance Biotherapeutics in a report on Thursday, March 31st. They issued a “sell” rating for the company. Two analysts have rated the stock with a sell rating, one has given a hold rating and ten have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $31.83.

Large investors have recently made changes to their positions in the stock. Neo Ivy Capital Management acquired a new position in Iovance Biotherapeutics during the 4th quarter valued at about $55,000. Metropolitan Life Insurance Co NY increased its position in Iovance Biotherapeutics by 69.3% during the 4th quarter. Metropolitan Life Insurance Co NY now owns 5,082 shares of the biotechnology company’s stock valued at $97,000 after buying an additional 2,080 shares in the last quarter. LPL Financial LLC increased its holdings in shares of Iovance Biotherapeutics by 11.5% in the third quarter. LPL Financial LLC now owns 18,109 shares of the biotechnology company’s stock valued at $447,000 after purchasing an additional 1,865 shares during the period. Amalgamated Bank increased its holdings in shares of Iovance Biotherapeutics by 5.7% in the fourth quarter. Amalgamated Bank now owns 28,214 shares of the biotechnology company’s stock valued at $539,000 after purchasing an additional 1,514 shares during the period. Finally, Allianz Asset Management GmbH increased its holdings in shares of Iovance Biotherapeutics by 101.8% in the fourth quarter. Allianz Asset Management GmbH now owns 53,500 shares of the biotechnology company’s stock valued at $1,025,000 after purchasing an additional 26,995 shares during the period. 94.37% of the stock is currently owned by institutional investors.

About Iovance Biotherapeutics (Get Rating)

Iovance Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma.

Read More